19 de Noviembre del 2019
On November 18, 2019, Golden State Medical Supply (GSM) issued a voluntary recall of Ranitidine 150mg capsules, and 300mg capsules due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.
Express Scripts will send a letter to patients who have received medication impacted by the recall.
The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.
|
Product Description |
GSMS NDC |
GSMS Lot # |
Expiration Date |
|
RANITIDINE HCl 150MG CAPSULES |
51407-097-05 |
GS023970 |
10/31/2020 |
|
|
|
GS026108 |
10/31/2020 |
|
|
|
GS026099 |
10/31/2020 |
|
|
|
GS026838 |
10/31/2020 |
|
|
|
GS025702 |
10/31/2020 |
|
|
|
GS027272 |
10/31/2020 |
|
|
|
GS027273 |
05/31/2021 |
|
RANITIDINE HCl 300MG CAPSULES |
51407-098-01 |
GS023971 |
10/31/2020 |
|
|
|
GS025527 |
10/31/2020 |
|
|
|
GS025526 |
10/31/2020 |
|
|
|
GS026114 |
10/31/2020 |
|
|
|
GS025813 |
10/31/2020 |
|
|
|
GS026189 |
10/31/2020 |
|
|
|
GS027555 |
07/31/2021 |
|
|
|
GS026190 |
05/31/2021 |
|
|
|
GS026220 |
05/31/2021 |
|
|
|
GS026584 |
05/31/2021 |
|
|
|
GS027139 |
05/31/2021 |
|
|
|
GS027554 |
05/31/2021 |
Additional information is available on the FDA’s website:
Última actualización: 08 de Diciembre del 2023